Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice
- Yulin Liao(corresponding author),
- Jianping Bin,
- Masanori Asakura,
- Wanling Xuan,
- Baihe Chen,
- Qiaobing Huang
- Southern Medical University,
- National Cerebral and Cardiovascular Center,
- Université libre de Bruxelles,
- The University of Osaka
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>AimsWe investigated the influence of type one cannabinoid receptor (CB1) deficiency on acute heart failure (AHF) and the underlying mechanism. Acute heart failure syndrome is an important clinical problem because of its high morbidity and mortality rates. Activation of CB1 induces vascular dilation and reinforces the properties of morphine, long-standing therapies for AHF syndrome, but the effect of endogenous CB1 activation on AHF is largely unknown.Methods and resultsAcute heart failure mouse model characterized by hypertension and pulmonary oedema was created by using transverse aortic constriction (TAC). Mortality, echocardiography, haemodynamic, morphology, and circulatory catecholamine levels in response to TAC were evaluated in CB1 knockout (KO) and wild-type mice. Type one cannabinoid receptor KO mice had a much higher mortality rate at 1 week after TAC attributable to AHF (65 vs. 11%, P< 0.001). One hour after TAC, CB1 KO mice had significant larger lung weight to body weight ratio (LW/BW, 14.53 + 1.09 mg/g in KO vs. 10.42 + 0.36 mg/g in WT, P < 0.01) and higher plasma epinephrine levels (9720 + 1226 pg/mL vs. 6378 + 832 pg/mL, P < 0.05). Pharmacological activation of CB1 reduced LW/BW in wild-type mice. Administration of epinephrine to wild-type TAC mice significantly increased left ventricular end-diastolic pressure and LW/BW, while CB1 agonists reduced the LW/BW and the plasma levels of catecholamine and increased myocardial activity of AMP-activated protein kinase. ConclusionEndogenous activation of CB1 in mice has cardiac protection in AHF, which is attributable to the inhibition of excessive sympathetic activation.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 3124-3133 (10 pages)Journal (Volume, Issue Number)
European Heart Journal (Volume 33, Issue 24)Publication milestones
- Published - 12/2012
Publication status
Published - 12/2012
ISSN
0195-668XPublication IDs
- Scopus: 84871180851
- PubMed: 21785110
Publication metrics
Metrics
SciVal
citations
21
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1
SciVal
FWCI
0.87
SciVal
Author count
10
SciVal
Paper percentile
79
PlumX, opens in new tab
Citation count
24
Captures
46
Funding Details
This work was supported by grants from the Department of Education of Guangdong Provincial Government and the Southern Medical University, China (to Y.L.), the Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan Heart Foundation, and Japan Cardiovascular Research Foundation (to M.K.).
